The U.S. Patent US9035074B2, titled "Abrocitinib and methods of use," was granted on May 16, 2015, and is associated with the drug abrocitinib [1]. This patent is listed on Google Patents [1].
When does abrocitinib patent protection expire?
The expiration of U.S. Patent US9035074B2 depends on several factors, including potential patent term extensions and any subsequent patents that may cover abrocitinib. Generally, U.S. patents have a term of 20 years from the filing date. Information regarding the specific expiration date and potential extensions for abrocitinib patents can be found through resources like DrugPatentWatch.com [2].
What is abrocitinib used for?
Abrocitinib is a Janus kinase 1 (JAK1) inhibitor used for the treatment of moderate-to-severe atopic dermatitis in adults [3]. It works by reducing inflammation [3].
Who developed abrocitinib?
Abrocitinib was developed by Pfizer [3].
What are the common side effects of abrocitinib?
Common side effects of abrocitinib include acne, upper respiratory tract infections, and herpes simplex infections [3].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is a targeted therapy that works differently from topical treatments or other systemic medications. As a JAK1 inhibitor, it aims to reduce the immune response contributing to atopic dermatitis. Comparisons with other treatments would involve evaluating efficacy, safety profiles, and administration routes.
Are there other patents related to abrocitinib?
Drug development often involves multiple patents covering different aspects of a drug, such as its chemical structure, synthesis, formulations, and methods of use. It is likely that other patents exist that also protect abrocitinib [1]. Resources like DrugPatentWatch.com can provide a comprehensive view of patent landscapes for specific drugs [2].
What is the mechanism of action for abrocitinib?
Abrocitinib selectively inhibits Janus kinase 1 (JAK1). JAKs are intracellular enzymes that help transmit signals from cytokine and growth factor receptors on the cell surface to the nucleus, influencing gene expression. By inhibiting JAK1, abrocitinib interferes with the signaling pathways of certain cytokines involved in inflammation and immune responses associated with atopic dermatitis [3].
What clinical trial data supports abrocitinib's use?
Clinical trials, such as the JAK1 Real World Evidence (RWE) study, have been conducted to evaluate the effectiveness and safety of abrocitinib in treating atopic dermatitis. These trials provide the basis for regulatory approval and inform clinical practice [4].
What are the regulatory approvals for abrocitinib?
Abrocitinib has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for the treatment of atopic dermatitis [3].
Sources:
[1] Google Patents: US9035074B2
[2] DrugPatentWatch.com
[3] FDA: FDA approves abrocitinib for atopic dermatitis
[4] JAK1 Real World Evidence study